https://www.dailymail.co.uk/health/article-11627695/Moderna-begins-trialing-mRNA-shot-injected-directly-HEART.html
Moderna begins trialing mRNA shot that is injected directly into the HEART to treat heart attack patients
The shot encodes for relaxin, a hormone which is known to improve blood flow
Patients have received the injection in a phase one trial looking at dosage levels
Moderna CEO Stphane Bancel told Sky News: 'It's like science fiction medicine'
Moderna is developing an mRNA shot that is injected directly into the hearts of heart attack and heart failure patients.
The 'vaccine' uses the same technology as the company's flagship Covid jab and is designed for people weeks or months after a heart attack to help them recover.
It works by instructing human heart cells to generate a hormone that is known to improve blood flow, helping restore damaged heart muscles.
During a heart attack, muscle cells can start to die and cannot be re-generated. Roughly one in five people who have had a heart attack will be readmitted to the hospital for a second one within five years.
Patients with stable heart failure have received the shot in a phase one clinical trial, Moderna said this week. The injection encodes for relaxin, a naturally occurring hormone that is known to improve blood flow
Patients with stable heart failure have received the shot in a phase one clinical trial, Moderna said this week. The injection encodes for relaxin, a naturally occurring hormone that is known to improve blood flow
This week, the drug maker announced that the first patients were given the injection in a phase one clinical trial.
Moderna CEO Stphane Bancel told Sky News Australia in October: 'We have now in the clinic a super exciting program where we inject mRNA into people's hearts after a heart attack to grow back new blood vessels to help revascularize the heart.
'It's a bit like science fiction medicine but that's what is really exciting to me.'
In its latest business update, Moderna this week announced that the first patients have been given the injection, called mRNA-0184, in a phase 1B clinical trial.
Moderna begins trialing mRNA shot that is injected directly into the HEART to treat heart attack patients
The shot encodes for relaxin, a hormone which is known to improve blood flow
Patients have received the injection in a phase one trial looking at dosage levels
Moderna CEO Stphane Bancel told Sky News: 'It's like science fiction medicine'
Moderna is developing an mRNA shot that is injected directly into the hearts of heart attack and heart failure patients.
The 'vaccine' uses the same technology as the company's flagship Covid jab and is designed for people weeks or months after a heart attack to help them recover.
It works by instructing human heart cells to generate a hormone that is known to improve blood flow, helping restore damaged heart muscles.
During a heart attack, muscle cells can start to die and cannot be re-generated. Roughly one in five people who have had a heart attack will be readmitted to the hospital for a second one within five years.
Patients with stable heart failure have received the shot in a phase one clinical trial, Moderna said this week. The injection encodes for relaxin, a naturally occurring hormone that is known to improve blood flow
Patients with stable heart failure have received the shot in a phase one clinical trial, Moderna said this week. The injection encodes for relaxin, a naturally occurring hormone that is known to improve blood flow
This week, the drug maker announced that the first patients were given the injection in a phase one clinical trial.
Moderna CEO Stphane Bancel told Sky News Australia in October: 'We have now in the clinic a super exciting program where we inject mRNA into people's hearts after a heart attack to grow back new blood vessels to help revascularize the heart.
'It's a bit like science fiction medicine but that's what is really exciting to me.'
In its latest business update, Moderna this week announced that the first patients have been given the injection, called mRNA-0184, in a phase 1B clinical trial.